The central action of lignocaine and its effect on cardiac output

Some pharmacological properties of o-methyl-alpha-propylaminopropioananilide, a new local anaesthetic

The anaesthetic action of o-methyl-alpha-propylaminopropionanilide (L 67, Astra) has been studied and compared with lignocaine in different in vitro and in vivo tests. Procaine and amethocaine (tetracaine) were also included in several of the comparisons. In nerve block on the isolated frog sciatic nerve L 67 is somewhat less effective than lignocaine. In all in vivo conditions, however, L 67 is quite comparable to lignocaine as to duration, latency and frequency of anaesthesia. As a spinal anaesthetic in rabbits 2 to 4% solutions of L 67 give a longer duration of anaesthesia than lignocaine. Toxicity in mice and rabbits and respiratory and circulatory effects in cats have also been evaluated. L 67 is almost twice as well tolerated as lignocaine. It is concluded that L 67 may prove to be a useful anaesthetic in certain clinical applications.

Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide

Since most of the toxicity associated with class 1B antiarrhythmic drugs is dose-related, this review examines adverse effects seen in both therapeutic practice and accidental or premeditated overdose. Toxicity is very common with these agents and can be life-threatening. A high percentage of patients must discontinue therapy because of adverse effects. Mexiletine and tocainide are structural analogues of lignocaine (lidocaine) and toxicity is similar with all 3 drugs. With gradual intoxication (the most common form) central nervous system effects such as lightheadedness, dizziness, drowsiness and confusion are seen first. Seizures and respiratory arrest can occur. Cardiovascular toxicity is manifested by progressive heart block, reduced cardiac contraction, hypotension and asystole. Both mexiletine and tocainide may have proarrhythmic effects. Gastrointestinal toxicity is also common. Shock, hypotension, cardiac failure and beta-blocker therapy reduce lignocaine clearance and enhance the risk of intoxication during routine therapy. Both lignocaine and mexiletine elimination is impaired in severe liver disease while tocainide clearance is reduced in renal failure. Management of toxicity is largely supportive and symptomatic. Lignocaine infusion must be discontinued and decontamination of the gut in the case of oral preparations is recommended. Serious intoxication requires intensive care unit admission. Haemodialysis or haemoperfusion may be helpful in serious lignocaine and tocainide poisoning. In institutions where extracorporeal circulatory assistance is available, massive lignocaine poisoning has been successfully treated with this intervention. In the therapeutic setting serious toxicity can be prevented by close clinical surveillance and appropriate dose reduction in patients with reduced drug clearance. Because of the large interindividual variation in lignocaine pharmacokinetic parameters, therapeutic drug monitoring is recommended if results can be reported quickly. Mexiletine and tocainide have stereoselective metabolism and assays do not distinguish the more active isomers. Therapeutic drug monitoring is less useful in this situation.

Disopyramide and lignocaine. A comparison of cardiac effects using echocardiography

1 The cardiac effects of disopyramide (D) and lignocaine (L) were measured and compared in normal volunteers (D n=4; L n=3) following the establishment of a series of three steady-state drug plasma concentrations spanning the therapeutic range (1.5-5 micrograms base ml-1). 2 During control and steady-state periods multiple measurements were made of heart rate, blood pressure, drug concentrations and echocardiographic measurement of cardiac dimensions and estimated left ventricular function. 3 No change in heart size or estimated function occurred with L except for a small increase in estimated cardiac output (+0.5 1 min-1) secondary to a small rise in heart rate (maximum +7 beats min-1). Blood pressure rose slightly (maximum +11 mmHg). 4 D caused an increase in heart size, marked at end systole (+0.63 cm), and a decrease in echo indices of ventricular function (25-33%). These changes were related to plasma drug concentration but were not reflected in cardiac output estimation since heart rate rose (+15 beats min-1). Blood pressure also rose (+10 mmHg). 5 Significant differences were shown between D and L at similar plasma drug concentrations. The negative inotropic effect of D may be greater than previously suggested and clinically important.

Use of lignocaine in treatment of cardiac arrhythmias

Images